

ID: OD-SAMPLE-001

Patient Information:

Name : Sample Patient (Indian demo)
Date of Birth: 12.04.1963
Sex at Birth: Male
Test Name: Comprehensive (All Drugs) Panel

Sample Information:

Date Collected: 20.06.2026
Date Received: 21.06.2026
Source: —
Result Date: 24.06.2026

Referring Doctor:

Name: Dr. A. Sharma
Hospital: 30M Genomics — Demo
Place: Hyderabad

COMPREHENSIVE (ALL DRUGS) PANEL — DRUG RESPONSE INFORMATION

39

GENES EVALUATED

590

 TOTAL DRUGS
ASSESSSED

0

AVOID

42

USE WITH CAUTION

548

SAFE & EFFICIENT

REPORT SUMMARY

Safe & Efficient
Use with Caution
High Risk

CARDIOLOGY

113 drug(s)

Drug Class	Safe & Efficient	Use with Caution	High Risk
ACE Inhibitors	Benazepril, Captopril, Enalapril, Imidapril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandolapril	-	-
Anaesthetic Agents	Lidocaine	-	-
Antiarrhythmics	Flecainide, Propafenone, Procainamide, Mexiletine, Amiodarone, Quinidine, Dronedarone, Dopamine	-	-
Anticoagulants	Warfarin, Acenocoumarol, Phenprocoumon, Dabigatran, Edoxaban	Apixaban, Rivaroxaban	-
Antidiabetic Agents	Canagliflozin, Empagliflozin	-	-
Antiplatelets	Clopidogrel, Prasugrel, Ticlopidine, Aspirin, Cilostazol, Vorapaxar	Ticagrelor	-
Beta Blockers	Metoprolol, Carvedilol, Nebivolol, Propranolol, Timolol, Atenolol, Bisoprolol, Bucindolol, Sotalol, Bufuralol, Talinolol, Betaxolol	-	-
Calcium Channel Blockers	-	Amlodipine, Felodipine, Nicardipine, Nisoldipine, Diltiazem, Verapamil, Nifedipine, Nimodipine, Nitrendipine	-
Disease-Modifying Antirheumatics	Colchicine	-	-
Diuretics	Torsemide, Furosemide, Hydrochlorothiazide	-	-
NSAIDs	Finerenone	-	-
Ophthalmic Agents	Latanoprost	-	-
Other	Losartan, Nitroglycerin, Isosorbide di/mononitrate, Valsartan, Fluindione, Spironolactone, Irbesartan, Candesartan, Telmisartan	-	-
Other Cardiovascular Agents	Hydralazine, Digoxin, Mavacamten, Minoxidil, Ranolazine, Sildenafil, Ivabradine, Eplerenone, Tolvaptan, Clonidine, Sodium Nitroprusside, Gemfibrozil, Ezetimibe, Aliskiren, Bosentan, Olmesartan,	-	-

Kukatpally, Hyderabad

ID: OD-SAMPLE-001

Patient Information:

Name : Sample Patient (Indian demo)
Date of Birth: 12.04.1963
Sex at Birth: Male
Test Name: Comprehensive (All Drugs) Panel

Sample Information:

Date Collected: 20.06.2026
Date Received: 21.06.2026
Source: —
Result Date: 24.06.2026

Referring Doctor:

Name: Dr. A. Sharma
Hospital: 30M Genomics — Demo
Place: Hyderabad

Drug Class	Safe & Efficient	Use with Caution	High Risk
	Sacubitril/Valsartan, Ambrisentan, Disopyramide, Doxazosin, Epinephrine, Macitentan, Norepinephrine, Riociguat, Selexipag, Vericiguat, Methyldopa		
Proton Pump Inhibitors	Omeprazole, Esomeprazole, Lansoprazole, Dexlansoprazole, Pantoprazole, Rabeprazole	-	-
Rare Disease and Enzyme Therapies	Lomitapide	-	-
Respiratory Agents	Phenylephrine	-	-
Statins	Simvastatin, Rosuvastatin, Atorvastatin, Pravastatin, Pitavastatin, Fluvastatin, Lovastatin, Cerivastatin	-	-

ONCOLOGY

64 drug(s)

Drug Class	Safe & Efficient	Use with Caution	High Risk
Antimetabolites	Mercaptopurine, Thioguanine, Fluorouracil, Capecitabine, Methotrexate (high-dose), Methotrexate, Mercaptopurine (IBD), Cytarabine, Tegafur, Floxuridine	-	-
Cytotoxic Chemotherapy	Cisplatin, Irinotecan, Doxorubicin, Daunorubicin, Cyclophosphamide, Carboplatin, Busulfan, Ifosfamide, Dacarbazine, Mitoxantrone, Topotecan, Bleomycin, Epirubicin, Mitomycin, Oxaliplatin, Procarbazine	Vincristine, Docetaxel, Etoposide, Paclitaxel	-
Endocrine Therapies	Tamoxifen, Letrozole, Anastrozole, Exemestane, Flutamide, Abiraterone, Raloxifene	-	-
Opioid Analgesics	Morphine	-	-
Other	Belinostat, Sacituzumab govitecan, Bortezomib	-	-
Supportive Care	Ondansetron, Tropisetron, Allopurinol, Granisetron, Palonosetron, Zoledronate (zoledronic acid), Dronabinol (THC), Cinacalcet, Methoxsalen	-	-
Targeted Therapies	Pazopanib, Nilotinib, Axitinib, Sorafenib, Erlotinib, Gefitinib, Belzutifan, Lapatinib, Regorafenib, Ruxolitinib	Sunitinib, Everolimus, Ibrutinib, Imatinib	-

HAEMATOLOGY & COAGULATION

15 drug(s)

Drug Class	Safe & Efficient	Use with Caution	High Risk
Anticoagulants	Warfarin, Acenocoumarol, Phenprocoumon	-	-

Patient Information:

Name : Sample Patient (Indian demo)
Date of Birth: 12.04.1963
Sex at Birth: Male
Test Name: Comprehensive (All Drugs) Panel

Sample Information:

Date Collected: 20.06.2026
Date Received: 21.06.2026
Source: —
Result Date: 24.06.2026

Referring Doctor:

Name: Dr. A. Sharma
Hospital: 30M Genomics — Demo
Place: Hyderabad

GENOTYPE SUMMARY OF THE PATIENT

Gene	Marker	Genotype result	Diplotype	Phenotype	Process affected (ADME)
CYP2C19	rs4244285; rs4986893; rs12248560	GG; GG; CC	*1/*1	Normal metabolizer	Metabolism
CYP2C9	rs1799853; rs1057910	CC; AA	*1/*1	Normal metabolizer	Metabolism
VKORC1	rs9923231	CC	—	Normal warfarin sensitivity	Pharmacodynamic response
CYP4F2	rs2108622	CC	*1/*1	Normal metabolizer	Metabolism
CYP3A4	rs35599367	GG	*1/*1	Normal metabolizer	Metabolism
CYP2B6	rs3745274	GG	*1/*1	Normal metabolizer	Metabolism
CES1	rs2244613; rs8192935	GG; AA	—	Normal metabolizer	Metabolism
SLCO1B1	rs4149056	TT	*1/*1	Normal transporter function	Distribution
ABCG2	rs2231142	GG	—	Normal predicted response	Absorption, Excretion
CYP2D6	rs3892097; rs1065852	CC; GG	*1/*1	Normal metabolizer	Metabolism
ADRB1	rs1801252; rs1801253	AA; GG	—	Typical beta-1 adrenergic response	Pharmacodynamic response
ADRB2	rs1042713; rs1042714	GG; GG	—	Typical beta-2 adrenergic response	Pharmacodynamic response
UGT1A1	rs8175347	*1/*1	*1/*1	Normal metabolizer	Metabolism
UGT2B7	rs7439366	TT	*1/*1	Normal metabolizer	Metabolism
ABCB1	rs1045642	AA	—	Normal predicted response	Absorption, Distribution
NAT2	rs1801280; rs1799930; rs1799931	TT; GG; GG	*1/*1	Rapid acetylator	Metabolism
ALDH2	rs671	GG	*1/*1	Normal predicted response	Metabolism
NOS3	rs1799983; rs2070744	TT; CC	—	Normal predicted response	Pharmacodynamic response
SULT1A1	rs1042028	CC	—	Normal metabolizer	Metabolism
CYP3A5	rs776746	TT	*1/*1	Expresser	Metabolism
TPMT	rs1800462; rs1800460	GG; GG	*1/*1	Normal metabolizer	Metabolism
NUDT15	rs116855232	CC	*1/*1	Normal metabolizer	Metabolism
COMT	rs4680	GG	—	Normal predicted response	Metabolism, Pharmacodynamic response
ERCC1	rs11615	AA	—	Normal predicted response	Pharmacodynamic response

ID: OD-SAMPLE-001

Patient Information:
Name : Sample Patient (Indian demo)

Date of Birth: 12.04.1963

Sex at Birth: Male

Test Name: Comprehensive (All Drugs) Panel

Sample Information:
Date Collected: 20.06.2026

Date Received: 21.06.2026

Source: —

Result Date: 24.06.2026

Referring Doctor:
Name: Dr. A. Sharma

Hospital: 30M Genomics — Demo

Place: Hyderabad

COMPREHENSIVE (ALL DRUGS) PANEL — DRUG RESPONSE BY CLASS

 Safe & Efficient
 Use with Caution
 High Risk

ACE INHIBITORS					
Drug	Gene & Phenotype	Diplotype / Genotype	Relevance & Effect	Recommendation & Key risks	Drug, Food & Other Interactions
Benazepril Evidence L3 · Safe & Efficient	ACE: Normal predicted response	rs4646994 - I/I	No pharmacogenomic concerns were identified for Benazepril from the genes assessed.	Standard dosing of Benazepril is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	Other factors: Kidney function; Adherence
Captopril Evidence L3 · Safe & Efficient	ACE: Normal predicted response	rs4646994 - I/I	No pharmacogenomic concerns were identified for Captopril from the genes assessed.	Standard dosing of Captopril is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	Other factors: Kidney function; Adherence
Enalapril Evidence L3 · Safe & Efficient	ACE: Normal predicted response CES1: Normal metabolizer	rs4646994 - I/I rs2244613 - GG / rs8192935 - AA	No pharmacogenomic concerns were identified for Enalapril from the genes assessed. This includes a provisional, functionally-inferred call for a non-standard genotype (see confidence).	Standard dosing of Enalapril is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	Other factors: Kidney function; Adherence
Imidapril Evidence L3 · Safe & Efficient	ACE: Normal predicted response	rs4646994 - I/I	No pharmacogenomic concerns were identified for Imidapril from the genes assessed.	Standard dosing of Imidapril is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	Other factors: Kidney function; Adherence
Lisinopril Evidence L3 · Safe & Efficient	ACE: Normal predicted response	rs4646994 - I/I	No pharmacogenomic concerns were identified for Lisinopril from the genes assessed.	Standard dosing of Lisinopril is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	Other factors: Kidney function; Adherence

ID: OD-SAMPLE-001

Patient Information:
Name : Sample Patient (Indian demo)

Date of Birth: 12.04.1963

Sex at Birth: Male

Test Name: Comprehensive (All Drugs)
Panel

Sample Information:
Date Collected: 20.06.2026

Date Received: 21.06.2026

Source: —

Result Date: 24.06.2026

Referring Doctor:
Name: Dr. A. Sharma

Hospital: 30M Genomics — Demo

Place: Hyderabad

ANAESTHETIC AGENTS — continued

Drug	Gene & Phenotype	Diplotype / Genotype	Relevance & Effect	Recommendation & Key risks	Drug, Food & Other Interactions
Bupivacaine Evidence L4 (informative) · Safe & Efficient	CYP3A4: Normal metabolizer CYP2D6: Normal metabolizer CYP1A2: Normal metabolizer	*1/*1 *1/*1 *1/*1	No pharmacogenomic concerns were identified for Bupivacaine from the genes assessed.	Standard dosing of Bupivacaine is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	May increase response: clarithromycin, itraconazole, ketoconazole, ritonavir/cobicistat, voriconazole, posaconazole, bupropion, fluoxetine, paroxetine, quinidine, terbinafine, fluvoxamine, ciprofloxacin, erythromycin, diltiazem, verapamil, fluconazole, grapefruit juice, duloxetine, mirabegron, cinacalcet, abiraterone, oral contraceptives, cimetidine May decrease response: rifampicin, carbamazepine, phenytoin, phenobarbital, St John's wort, rifabutin, tobacco smoke, omeprazole Food: Grapefruit, Seville orange & pomelo juice; Tobacco smoke & char-grilled food Other factors: Kidney function; Adherence
Dexmedetomidine Evidence L4 (informative) · Safe & Efficient	UGT1A4: Normal metabolizer	*1/*1	No pharmacogenomic concerns were identified for Dexmedetomidine from the genes assessed.	Standard dosing of Dexmedetomidine is appropriate on the basis of the genes assessed. Key risks: No specific pharmacogenomic monitoring beyond routine care for this drug.	Other factors: Kidney function; Adherence